Bioventix plc
(“Bioventix” or the “Company”)
Issue of
Equity
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
it has applied for 46,661 ordinary shares of 5 pence each (the “Option Shares”) to be admitted
to trading on AIM (“Admission”). It is expected that Admission will
occur and that dealings will commence in the Option Shares on
28 January 2020.
The Option Shares are being issued pursuant to the exercise of
options by employees of the Company. The Option Shares will rank
pari passu with the existing ordinary shares of 5 pence each in the capital of the Company
("Ordinary Shares").
The total number of Ordinary Shares in issue following Admission
will be 5,189,335 and the Company holds no shares in treasury.
Therefore, the total number of Ordinary Shares with voting rights
in the Company will be 5,189,335.
The above figure of 5,189,335 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Bioventix under the FCA’s Disclosure Guidance and
Transparency Rules.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
